| 贺松敏,王宝喜,江杨阳,贾志楠,白保亮.终末期肾病维持性血液透析患者β2-MG、EOS水平与颈动脉粥样硬化及预后的关系[J].,2023,(11):2178-2182 |
| 终末期肾病维持性血液透析患者β2-MG、EOS水平与颈动脉粥样硬化及预后的关系 |
| Relationship between β2-MG and EOS Levels and Carotid Atherosclerosis and Prognosis in Patients with End-Stage Renal Disease on Maintenance Hemodialysis |
| 投稿时间：2022-10-22 修订日期：2022-11-17 |
| DOI：10.13241/j.cnki.pmb.2023.11.035 |
| 中文关键词: 终末期肾病 维持性血液透析 颈动脉粥样硬化 β2-MG EOS 预后 预测效能 |
| 英文关键词: End-stage renal disease Maintenance hemodialysis Carotid atherosclerosis β2-MG EOS Prognosis Predictive efficacy |
| 基金项目:河北省医学科学研究重点课题计划项目（20191065） |
|
| 摘要点击次数: 621 |
| 全文下载次数: 364 |
| 中文摘要: |
| 摘要 目的：探讨终末期肾病维持性血液透析（MHD）患者β2微球蛋白（β2-MG）、嗜酸性粒细胞（EOS）计数水平与颈动脉粥样硬化（CAS）及预后的关系。方法：选取2018年1月至2019年6月河北燕达医院收治的121例终末期肾病MHD患者，根据颈动脉粥样硬化发生情况分为CAS组（58例）和无CAS组（63例），检测并比较两组患者的血清?茁2-MG水平、EOS计数。所有患者出院后随访3年。多因素Logistic回归分析影响终末期肾病MHD患者预后的因素，受试者工作特征（ROC）曲线分析β2-MG、EOS预测终末期肾病MHD患者预后的价值。结果：CAS组血清β2-MG水平，外周血中EOS计数高于无CAS组（P＜0.05）。死亡组血清β2-MG水平，外周血中EOS计数高于生存组（P＜0.05）。合并CAS、高β2-MG、高EOS计数是终末期肾病MHD患者死亡的危险因素（P＜0.05）。β2-MG、EOS联合预测终末期肾病MHD患者预后的曲线下面积为0.904，高于单独指标预测。结论：终末期肾病MHD伴CAS患者血清β2-MG水平和外周血EOS计数增高，且与预后有关，联合检测β2-MG和EOS可提高终末期肾病MHD患者预后的预测效能。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the relationship between β2 microglobulin (β2-MG) and eosinophilic granulocytes (EOS) count levels and carotid atherosclerosis(CAS) and prognosis in patients with end-stage renal disease on maintenance hemodialysis (MHD). Methods: 121 patients with end-stage renal disease on MHD who were admitted to Hebei Yanda Hospital from January 2018 to June 2019 were selected, and they were divided into CAS group (58 cases) and non-CAS group (63 cases) according to the occurrence of carotid atherosclerosis. Serum β2-MG level and EOS counts in the two groups were detected and compared. All patients were followed up for 3 years after discharge. Multivariate Logistic regression analysis was conducted to analyze the prognostic factors of patients with end-stage renal disease on MHD, and receiver operating characteristic (ROC) curve was used to analyze the prognostic value of β2-MG and EOS in patients with end-stage renal disease on MHD. Results: Serum β2-MG level and peripheral blood EOS count in the CAS group were higher than those in the non-CAS group(P＜0.05). Serum β2-MG level and peripheral blood EOS count in the death group were higher than those in the survival group(P＜0.05). Combined with CAS, high β2-MG and high EOS count were risk factors for death in patients with end-stage renal disease on MHD (P＜0.05). The area under curve of combining the β2-MG and EOS predicted the prognosis of patients with end-stage renal disease on MHD was 0.904, which was higher than that predicted by single indexes. Conclusion: Serum β2-MG level and peripheral blood EOS count are increased in patients with end-stage renal disease on MHD with CAS, and which are associated with prognosis, the combined detection of β2-MG and EOS can improve the predictive efficacy of prognosis in patients with end-stage renal disease on MHD. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
